Not immediately
This reduces material waste, supports procedural efficiency, and lowers the risk of accidental microbial introduction during repeated laboratory manipulation
This product is sold exclusively to qualified professionals, research institutions, and authorized laboratories operating under applicable institutional guidelines
The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients
Heres What the Process Looks Like: Consultation Discuss your goals and symptoms Customized Plan Determine the right dosage and frequency Injection Administered in minutes with minimal discomfort Aftercare No downtime
